- The P-II SERENITY study involves assessing mirikizumab (200/600/1000mg) vs PBO in patients in a ratio (2:1:1:2) with mod. to severely active CD for 12wks.
- Patients showed improvement in fatigue @12wks. as measured by the mean change in FACIT-Fatigue scores with improvements that sustained up to 1yr. At the end of the 12wks. period, patients treated with mirikizumab who achieved ≥1 point improvement in SES-CD were re-randomized in a ratio (1:1) to continue to receive the same, once-monthly mirikizumab (IV or SC, 300mg), up to 52wks.
- Three analyses of the RWE data also highlight the burden of fatigue and rectal urgency among people living with UC and CD
Click here to read full press release/ article | Ref: PRNewswire | Image: Forbes